***SMALL CAP NATION***

[Lotto123]

4. Celsion (CLSN_)

This is the only biotech stock I'm focusing on right now.

Celsion has developed ThermoDox, which is a heat-activated drug delivery technology currently in Phase III testing for liver cancer.

As with many biotechs, the company must keep reloading the balance sheet with more cash to stay afloat, which has heavily pressured shares.

The good news: Investors need not wait years and instead just a few more quarters to analyze that Phase III data.

If the news is good, then Celsion is likely to pop up on the radar of many biotech investors.

In a best-case scenario, ThermoDox could be selling in Europe and China in the first half of 2013, and in the U.S. in the second half of the year.

Management will provide a progress report when first-quarter results are released in mid-May